Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dNAvCfbwoceHlsrpVyrd

August 7, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
How Much Do You Really Need to Make? The Answer May Shock You
Rather than focus on what you can afford to pull out of the business to cover your living expenses, you need to focus on how much you need to earn at your business in order to afford the lifestyle you want to have. This is where the Personal Earnings Goal, or PEG, comes into play. Learn how to calculate your PEG and find out how much you really need to make.

  Health Care & Policy 
 
  • Boehringer teams up with XOMA and Servier on uveitis drug
    Boehringer Ingelheim signed a deal with XOMA and Les Laboratoires Servier to manufacture gevokizumab, XOMA's novel interleukin 1-beta allosteric modulating antibody, at Boehringer's German facility for Servier's commercial use. XOMA's process and technology for commercial production will be transferred to Boehringer. Gevokizumab is in late-stage development for non-infectious uveitis. Pharmaceutical Business Review Online (8/6) LinkedInFacebookTwitterEmail this Story
  • Biomedical firm and Navy collaborate on hemorrhagic shock drug
    Oxygen Biotherapeutics and the Naval Medical Research Unit of San Antonio agreed to research and develop perfluorocarbon-based drug candidate Oxycyte to treat hemorrhagic shock. Oxygen will examine the treatment's effectiveness and safety and look at hemoglobin-based oxygen carriers as possible therapy. The collaboration complements the Navy's research on Oxycyte's therapeutic potential against traumatic brain injury and decompression sickness. Pharmaceutical Business Review Online (8/3) LinkedInFacebookTwitterEmail this Story
  • Pluristem eyes orphan-drug status for placental stem cell therapy
    Pluristem Therapeutics plans to file with the FDA an orphan-drug application for stem cell treatment Placental eXpanded for aplastic bone marrow. The drugmaker said PLX saved the life of a 54-year-old Israeli woman with terminal bone marrow failure, the second successful treatment in three months. "The result of this unique case demonstrates that PLX cells could potentially be effective for use in cancer patients," Hadassah Medical Center's Reuven Or said. Globes (Israel) (8/6) LinkedInFacebookTwitterEmail this Story
  • Silk stabilizers shield vaccines, antibiotics against heat
    A silk-based stabilizer developed with support from the NIH allowed some vaccines and antibiotics to maintain stability when stored in temperatures up to 140 degrees Fahrenheit. The researchers used silk films to protect bioactive molecules in antibiotics and vaccines against the effects of high storage temperatures and exposure to light. The silk stabilizers could become an alternative to refrigeration. MedCityNews.com (8/5) LinkedInFacebookTwitterEmail this Story
 
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Company & Financial News 
  Global Developments 
  • U.K. government and pharma to negotiate drug pricing in September
    The U.K. Health Department and the Association of the British Pharmaceutical Industry plan to begin talks next month on a drug-pricing framework that is set to start in 2014. Health Minister Andrew Lansley advocated "value-based pricing," raising concern among drugmakers that the government will end up using rigid assessment to price medications. However, the change will be evolutionary, rather than revolutionary, the two sides said. Reuters (8/3) LinkedInFacebookTwitterEmail this Story
First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.
  Featured Content 
 

  Food & Agriculture 
  • Ganeden receives GRAS notice from FDA
    An FDA notice indicated no question or objection to the Generally Recognized As Safe status of Ganeden Biotech's probiotic ingredient. The notice clears GanedenBC30 for use in baked goods, beverages and other food items. FoodBusinessNews.net (free registration) (8/3) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Fiberight gets federal nod in waste-to-fuel process
    Fiberight has secured a key federal approval for its process of producing advanced biofuels from industrial and municipal waste. Fiberight demonstrated it can remove recyclable waste from organic waste, the company said. Fiberight plans a facility in Lawrenceville, Va., with the capacity of nearly 1 million gallons of biofuels annually. DomesticFuel.com (8/6) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
He who fears he shall suffer, already suffers what he fears."
--Michel de Montaigne
French philosopher and statesman


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information